Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immnoconjugate Therapy in Patients with B-Cell Non-Hodgkin Lymphoma

Authors

Aliza Gardenswartz, New York Medical CollegeFollow
Karen Seiter, New York Medical CollegeFollow
J Hochberg, New York Medical CollegeFollow
E Morris
L HarrisonFollow
Yaya Chu, New York Medical CollegeFollow
J Basso
P Gerard, New York Medical CollegeFollow
H Islam, New York Medical CollegeFollow
Janet Ayello, New York Medical CollegeFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

10-2022

DOI

10.1016/S0145-2126(22)00227-2

Journal Title

Leukemia Research

Department

Medicine

Second Department

Pediatrics

Third Department

Radiology

Recommended Citation

Gardenswartz, A., Seiter, K., Hochberg, J., Morris, E., Harrison, L., Chu, Y., Basso, J., Gerard, P., Islam, H., Ayello, J., & Cairo, M. S. (2022). Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immnoconjugate Therapy in Patients with B-Cell Non-Hodgkin Lymphoma. Leukemia Research, 121 (Suppl.), S24-S25. https://doi.org/10.1016/S0145-2126(22)00227-2